ALFA Finder
19:31 IST
BSE
Earnings Call
Zydus Lifesciences Earnings Call: Key Takeaways
Zydus delivered a record-breaking FY26 with 17% revenue growth and peak EBITDA margins of 31.2%, significantly exceeding internal expectations.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd news stories on ALFA NewsRead the news →- Share price
- ₹1,199.50
- Market cap
- ₹1,20,698 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 28.9×Sector 43.8×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Business Update 9Merger & Restructuring 8Other Announcement 7Earnings Call 7Acquisition 6Management Change 4Legal & Regulatory 4Financial Results 4Regulatory Approval 3Product Launch 3Board Meeting Date 3Results Update 2Promoter Buying (Off-Market) 2Annual General Meeting 2Price Movement Clarification 1Partnership 1Dividend 1Credit Rating 1Capital Structure Change 1Capacity Expansion 1Annual Report 1Adverse Business Impact 1
Time
72 announcements with these filters
14:21 IST
BSE
Results Update
Zydus Lifesciences Results Update
Zydus Lifesciences reported FY26 revenues of ₹27,148 Crore and approved a ₹1,100 Crore share buyback. Strong performance across segments supports the multi-year growth outlook.
- Value
- ₹1,100 Cr
14:19 IST
NSE
Earnings Call
Zydus Lifesciences Earnings Call: Key Takeaways
Zydus Lifesciences reported strong FY26 performance with 16% YoY revenue growth and EBITDA margins expanding to 31.2%. Strategic focus remains on US specialty/rare diseases and domestic chronic therapy leadership.
14:18 IST
BSE
Dividend
Zydus Lifesciences Dividend
Zydus Lifesciences declared a final dividend of Re. 1 per share for FY2026. The record date is July 24, 2026, pending shareholder approval.
14:15 IST
NSE
Management Change
Zydus Lifesciences Management Change
Zydus Lifesciences re-appointed Dr. Sharvil P. Patel as Managing Director and appointed Mr. Kulin S. Lalbhai as Independent Director. Both roles carry five-year terms.
- Execution
- 5 years
14:13 IST
NSE
Merger & Restructuring
Zydus Lifesciences Merger & Restructuring Worth ₹1,100 Cr
Zydus Lifesciences approved a ₹1,100 Crore share buyback at ₹1,150 per share. The tender offer targets 95,65,217 shares, representing a significant premium to market price.
- Value
- ₹1,100 Cr
14:08 IST
BSE
Financial Results
Zydus Lifesciences Q4 FY26 Results: Net Profit ₹1,272 Cr, Up 8.7% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹7,587 Cr (+16.2% YoY) and net profit of ₹1,272 Cr (+8.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹1,272 Cr · +8.7% YoY
14:07 IST
BSE
Financial Results
Zydus Lifesciences Financial Results
Zydus Lifesciences reported consolidated net profit of ₹5,040 Crore for FY26. The board recommended a 100% final dividend of ₹1 per equity share.
20:37 IST
BSE
Acquisition
Zydus Lifesciences Acquisition Worth ₹1,581 Cr
Zydus Lifesciences is acquiring Assertio Holdings for approximately ₹1580.8 Crore in cash. The deal establishes an immediate U.S. specialty oncology commercial footprint and infrastructure.
- Value
- ₹1,581 Cr
- Execution
- Financial year 2026-27
17:18 IST
NSE
Legal & Regulatory
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences received an appeal order upholding a ₹1.18 Crore GST demand and penalty. The company intends to file a second appeal before GSTAT.
- Value
- ₹1.18 Cr
15:55 IST
BSE
Board Meeting Date
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences will hold a board meeting on May 19, 2026, to consider a share buyback proposal. The trading window remains closed until May 21.
10:14 IST
NSE
Management Change
Zydus Lifesciences Management Change
Mr. Apurva S. Diwanji ceased to be an Independent Director at Zydus Lifesciences following his tenure completion. The change was effective from May 12, 2026.